PITTSBURGH — Mylan on Tuesday announced that it had launched its generic of Jazz Pharmaceuticals’ FazaClo (clozapine) orally disintegrating tablets. The drug, which will be available in 25- and 100-mg dosage strengths, is indicated as a treatment for schizophreniain patients who don’t respond adequately to standard treatments.
The tablets had U.S. sales of about $51.1 million for the 12 months ended Sept. 30.